Industry Perspectives

Well-calibrated metrics reveal that AI virtual cells can reliably identify biologically significant signals and accelerate target discovery pipelines.

The acquisition brings together two leaders in scientific software to provide end-to-end support from molecular design and analytical characterization to manufacturing quality control.

A collaborative effort to co-develop scalable and reproducible sample preparation workflows for proteomics

Paired with OGT’s Interpret platform, the solution allows labs to visualise MRD dynamics over time and streamline workflows while maintaining accuracy and reproducibility.

Award-winner Cheng Lyu shows how tiny changes in circuit wiring can shift an animal’s behavior, illuminating the developmental rules of the nervous system.

Qureight’s Vascul8 model uses AI to analyse CT scans and identify patients at risk of residual pulmonary hypertension after surgery.

Lonza strengthens its pharmaceutical quality control portfolio through the acquisition of Redberry, enabling faster and more reliable microbial testing.

Ongoing collaboration aims to bring new treatments for neurodegenerative conditions closer to patients.

Ryvu’s ONCO Prime platform uncovers novel molecular vulnerabilities and actionable targets in colorectal and other cancers.

Company is first to deliver ultra-long, fully verified DNA in less than 25 days, backed by the industry’s only on-time guarantee

Under the new partnership, Biodesix will lead development and regulatory efforts for Bio-Rad’s ddPLEX ESR1 assay, enabling sensitive ctDNA-based mutation testing.

Enamine’s chemistry platform delivered over 2,000 novel compounds to accelerate the discovery of pre-clinical candidate ASAP-0017445.